Compounds > cg100649
Page last updated: 2024-12-11

cg100649

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CG100649: a cyclooxygenase-2 inhibitor with both anti-inflammatory and antineoplastic activities; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9841854
CHEMBL ID166863
SCHEMBL ID3233093
MeSH IDM000607620

Synonyms (43)

Synonym
cg100649
polmacoxib
CHEMBL166863
cg-100649
polmacoxib [usan]
1427301-99-2
polmacoxib [inn]
4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl]-benzenesulfonamide
polmacoxib [who-dd]
benzenesulfonamide, 4-(3-(3-fluorophenyl)-4,5-dihydro-5,5-dimethyl-4-oxo-2-furanyl)-
polmacoxib [usan:inn]
cg 100649
unii-ij34d6ypao
301692-76-2
4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide
ij34d6ypao ,
IJWPAFMIFNSIGD-UHFFFAOYSA-N
5-{4-(aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2h)-furanone
SCHEMBL3233093
polmacoxib (usan/inn)
D10656
AKOS025149767
acelex (s. korea)
4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxofuran-2-yl]benzenesulfonamide
gtpl8316
J-690277
2-(4-tert-butylphenyl)-1h-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1h-benzimidazole
4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxidanylidene-furan-2-yl]benzenesulfonamide
EX-A601
bdbm50474760
4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide
DB12399
BCP15550
cg100649; cg-100649; cg 100649
FT-0700281
Q19598695
SB17177
A857030
MS-25723
polmacoxibcg100649
DTXSID901029389
CS-0012326
HY-16726

Research Excerpts

Overview

CG100649 is a novel anti-inflammatory drug that is currently under development. It is a new member of the COXIB family, which is proposed to inhibit both COX-2 and carbonic anhydrase (CA) activity.

ExcerptReferenceRelevance
"CG100649 is a new member of the COXIB family, which is proposed to inhibit both COX-2 and carbonic anhydrase-I/-II (CA-I/-II) activity."( CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models.
DuBois, RN; Holla, VR; Katoh, H; Kim, SH; Margalit, O; Wang, D; Wu, H; Xia, D; Yang, P, 2014)		2.57
"CG100649 is a novel anti-inflammatory drug that is currently under development. "( Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women.
Bae, KS; Jin, S; Jung, JA; Kim, MJ; Kim, YH; Lim, HS; Noh, YH, 2015)		2.09
"CG100649 is a novel NSAID dual inhibitor for COX-2 and carbonic anhydrase (CA)-I/-II."( Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment wit
Cho, JM; Jang, YS; Kang, JH; Kim, HM; Lee, SJ; Oh, SH; Ro, S; Woo, JK, 2015)		1.36
"CG100649 is a novel NSAID proposed to inhibit both COX-2 and carbonic anhydrase (CA)-I/-II."( Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.
Alamuddin, N; Cen, L; Fitzgerald, GA; Lawson, JA; Propert, KJ; Skarke, C, 2012)		1.31

Toxicity

ExcerptReferenceRelevance
" CG100649 demonstrates a dual mechanism of action on cyclooxygenase-2 and carbonic anhydrase that may result in favorable treatment effects and few adverse gastrointestinal and cardiovascular events."( Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women.
Bae, KS; Jin, S; Jung, JA; Kim, MJ; Kim, YH; Lim, HS; Noh, YH, 2015)		1.56
" The most frequently encountered adverse events were aphthous stomatitis and dyspepsia."( Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women.
Bae, KS; Jin, S; Jung, JA; Kim, MJ; Kim, YH; Lim, HS; Noh, YH, 2015)		0.65
" However, their use is associated with serious dose-dependent gastrointestinal (GI), cardiovascular, renal, and hepatic adverse effects, which pose a serious clinical concern for both patients and physicians."( Evolving therapeutic strategies to improve nonsteroidal anti-inflammatory drug safety.
Cryer, B; McCarberg, BH, )		0.13
" Other outcome measures included adverse events (AEs), laboratory tests, vital signs, electrocardiograms, and physical examinations."( A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis.
Bin, SI; Cho, S; Choi, CH; Han, SB; In, Y; Kang, SB; Kim, J; Kim, JG; Kim, YM; Kyung, HS; Lee, BK; Lee, M; Moon, YW; Yoo, J, 2017)		0.46
" The results obtained during the 18-week trial extension with polmacoxib 2 mg were consistent with those observed during the 6-week treatment period, indicating that polmacoxib can be considered safe for long-term use based on this relatively small scale of study in a Korean population."( A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis.
Bin, SI; Cho, S; Choi, CH; Han, SB; In, Y; Kang, SB; Kim, J; Kim, JG; Kim, YM; Kyung, HS; Lee, BK; Lee, M; Moon, YW; Yoo, J, 2017)		0.46

Pharmacokinetics

ExcerptReferenceRelevance
"The objective of this study was to evaluate the safety, pharmacokinetic, and pharmacodynamic profiles of administering multiple oral doses of CG100649 to healthy Korean volunteers."( Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women.
Bae, KS; Jin, S; Jung, JA; Kim, MJ; Kim, YH; Lim, HS; Noh, YH, 2015)		0.85
" Blood samples for pharmacokinetic analysis were obtained ≤480 hours after the last dose."( Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women.
Bae, KS; Jin, S; Jung, JA; Kim, MJ; Kim, YH; Lim, HS; Noh, YH, 2015)		0.65
" This study explored the population pharmacokinetic and pharmacodynamic characteristics of polmacoxib."( Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis.
Bae, KS; Cho, JM; Cho, YS; Choi, SC; Lim, HS, 2022)		0.72
"Nonlinear mixed-effects modeling was performed using pooled pharmacokinetic data from a Phase I study in healthy individuals and pharmacokinetic properties and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) data from a Phase IIb study in patients with osteoarthritis."( Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis.
Bae, KS; Cho, JM; Cho, YS; Choi, SC; Lim, HS, 2022)		0.72
"The current model accurately characterized the pharmacokinetic and pharmacodynamic properties of polmacoxib and could provide a basis for individualized drug therapy."( Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis.
Bae, KS; Cho, JM; Cho, YS; Choi, SC; Lim, HS, 2022)		0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin G/H synthase 1Mus musculus (house mouse)IC50 (µMol)0.00300.00072.08445.1000AID1532180
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID234556Selectivity against COX-2 over COX-12004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
AID183650Inhibition of carrageenan-induced rat foot oedema following 3 mg/kg administration.2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
AID160565In vitro inhibitory activity against prostaglandin G/H synthase 2 using mouse peritoneal macrophage method2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
AID1532180Inhibition of COX-1 in LPS-induced mouse peritoneal macrophages2019European journal of medicinal chemistry, Jan-15, Volume: 162Medicinal chemistry of vicinal diaryl scaffold: A mini review.
AID178664Antiinflammatory activity was determined by measuring adjuvant-induced arthritis in rats using preventive method; dose administered daily twice2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
AID161996In vitro inhibitory activity against prostaglandin G/H synthase 1 using mouse peritoneal macrophage method2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
AID178667Antiinflammatory activity was determined by measuring adjuvant-induced arthritis in rats using therapeutic method; dose administered daily twice2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
AID178666Antiinflammatory activity was determined by measuring adjuvant-induced arthritis in rats using therapeutic method; dose administered daily once2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
AID168048Ability of compound to cause gastric ulcerogenicity was determined in rats at 5 mg/kg2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's8 (80.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.84 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (27.27%)5.53%
Reviews2 (18.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (54.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
celecoxib
[no description available]		11.9642organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
dup 697
DuP 697: structure given in first source		3.3110thiophenes
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.0210aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
rofecoxib
[no description available]		3.5720butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
valdecoxib
[no description available]		3.5720isoxazoles;
sulfonamide		antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
mk 0663
[no description available]		3.5720bipyridines;
organochlorine compound;
sulfone		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
cimicoxib
cimicoxib: a COX-2 inhibitor; structure in first source. cimicoxib : An imidazole substituted at positions 1, 4 and 5 by 4-aminosulfonylphenyl, chloro and 3-fluoro-4-methyoxyphenyl groups respectively. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs.		3.3110aromatic ether;
imidazoles;
organochlorine compound;
organofluorine compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
sc 57666
[no description available]		3.3110stilbenoid
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.110prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
6-ketoprostaglandin f1 alpha
6-Ketoprostaglandin F1 alpha: The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.. 6-oxoprostaglandin F1alpha : A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.		4.3711prostaglandins Falphahuman metabolite;
mouse metabolite
2,3-dinor-6-ketoprostaglandin f1alpha
2,3-dinor-6-ketoprostaglandin F1alpha: formed from 6-keto-PGF1alpha by Mycobacterium rhodochrous; RN given refers to (1R-(1alph,2beta(1E,3S*)))-isomer; structure given in first source. 2,3-dinor-6-oxoprostaglandin F1alpha : A prostanoid that is prostaglandin F1alpha lacking two methylenes in the carboxyalkyl chain and bearing an oxo group at the 6-position.		4.37114-oxo monocarboxylic acid;
prostanoid;
secondary alcohol		metabolite
thromboxane b2
Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.		4.3711thromboxanes Bhuman metabolite;
mouse metabolite
gw406381x
GW406381X: cyclooxygenase-2 inhibitor		3.3110
mobic
Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.		2.02101,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
ConditionIndicatedRelationship StrengthStudiesTrials
Adjuvant Arthritis
[description not available]		02.0210
Anasarca
[description not available]		02.0210
Gastric Ulcer
[description not available]		02.0210
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.0210
Stomach Ulcer
Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		02.0210
Arthritis, Degenerative
[description not available]		02.4110
Osteoarthritis
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.		14.4110
Osteoarthritis of Knee
[description not available]		03.5311
Cholera Infantum
[description not available]		03.5311
Coxarthrosis
[description not available]		03.5311
Osteoarthritis, Hip
Noninflammatory degenerative disease of the hip joint which usually appears in late middle or old age. It is characterized by growth or maturational disturbances in the femoral neck and head, as well as acetabular dysplasia. A dominant symptom is pain on weight-bearing or motion.		15.5311
Osteoarthritis, Knee
Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)		15.5311
Musculoskeletal Pain
Discomfort stemming from muscles, LIGAMENTS, tendons, and bones.		03.5311
Adenoma, Basal Cell
[description not available]		02.110
Carcinoma, Anaplastic
[description not available]		02.110
Colorectal Cancer
[description not available]		02.110
Adenoma
A benign epithelial tumor with a glandular organization.		07.110
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		07.110
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.110
Cancer of Colon
[description not available]		02.1110
Cancer of Lung
[description not available]		02.1110
Colonic Neoplasms
Tumors or cancer of the COLON.		02.1110
Intestinal Polyps
Discrete abnormal tissue masses that protrude into the lumen of the INTESTINE. A polyp is attached to the intestinal wall either by a stalk, pedunculus, or by a broad base.		02.1110
Lung Neoplasms
Tumors or cancer of the LUNG.		02.1110
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		04.3711